Pharmaceutical

Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn

Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of RayzeBio in a total equity value of nearly $4.1bn.

Dec 28, 2023 - 18:00
Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of RayzeBio in a total equity value of nearly $4.1bn.
Read the original article

Tags:

Previous Article

AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal

Next Article

Difficult biotech investment ecosystem forces focus on value

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Evotec shuts down gene therapy business in light of Q1 2024 loss 

Evotec shuts down gene therapy business in light of Q1 ...

May 23, 2024

STAT+: Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to deaths

STAT+: Pharmalittle: EU delays pharma legislation again...

Mar 24, 2023

Small Molecule to Target PSMA for Metastatic Hormone Re...

Jun 18, 2024